GlassScriptPhysician profile
Jeffrey Leamon Beaird
NPI 1821415621
$2,236.60
in general payments reported to CMS, 2019-2025
22 companies · $866 in 2025
The $866 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $635 · 2023: $161 · 2024: $457 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428 · Education: $55.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.45 |
| Education | $55.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $434.18 | 2022-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $184.16 | 2021-2025 | Jynarque |
| Aurinia Pharma U.S., INC. | $156.62 | 2021-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $152.13 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $149.66 | 2022-2024 | Acthar |
| Akebia Therapeutics INC | $134.87 | 2021-2025 | Vafseo |
| Ardelyx, INC. | $131.21 | 2023-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $106.26 | 2021-2025 | Rayaldee |
| Vantive US Healthcare LLC | $104.90 | 2025 | |
| Alnylam Pharmaceuticals INC. | $99.03 | 2025 | Givlaari |
| Novartis Pharmaceuticals Corporation | $92.83 | 2024-2025 | |
| Amgen INC. | $92.54 | 2022-2025 | Tavneos, Krystexxa |
| Glaxosmithkline, LLC. | $92.01 | 2021-2022 | |
| Travere Therapeutics, INC. | $64.39 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.32 | 2024-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.96 | 2022-2025 | Wegovy |
| Daiichi Sankyo INC. | $33.15 | 2024-2025 | Injectafer |
| Calliditas Therapeutics US INC. | $33.04 | 2025 | Tarpeyo |
| Ultragenyx Pharmaceutical INC. | $23.18 | 2025 | Crysvita |
| Alexion Pharmaceuticals, INC. | $19.18 | 2022 | |
| Lilly USA, LLC | $18.00 | 2025 | Jardiance |
| Baxter Healthcare | $14.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Beaird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.